Newsletter: December 2019

WuXi Vaccines to Build a $240 Million Manufacturing Facility in Ireland

WuXi Biologic’ subsidiary WuXi Vaccines, engaged in human vaccine Contract Development & Manufacturing Organization (CDMO) business, will invest $240 million to build a new vaccine manufacturing facility in Ireland. This investment follows the 20-year manufacturing Letter of Intent signed by WuXi Vaccines earlier this year. Read More

Partner News

Biologic Products DNA to IND Timeline in 9 Months – Yes It Can Be Done! Read More

WuXi Biologics Congratulates Tychan for Dosing First Patient of a Zika Antibody after Record 9 Months of Development Read More

WuXi Biologics Congratulates Tychan on First-in-Class Monoclonal Antibody for Yellow Fever after Record 7 Months of Development Read More

Antibody Drug Conjugate / Bioconjugates

Antibody Drug Conjugate (ADC) Development and Manufacturing Challenges & Solutions Read More

WuXi Biologics to Expand Integrated Biologics Conjugation Solution Center to Include Commercial Manufacturing Read More

WuXiBody™ Bispecific Antibody News

New Flexible Bispecific Antibody Format Demonstrates Improved Therapeutic Properties And Manufacturability Read More

WuXi Biologics Announced Exclusive Discovery Research with Brii Biosciences for Novel Bispecific Antibody Immunotherapeutics Read More

I-Mab Biopharma Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Three Bispecific Antibody Programs Read More

WuXiUP™ Platform News

Is Continuous Biomanufacturing a Good Fit for Your Process? Read More

WuXi Biologics Achieves Breakthrough Titer of 51g/L in Cell Culture Productivity Read More

Resources

From Concept to Market – Unique approaches in Biomanufacturing (Webinar)

Advanced Process Development Using Automated Micro Bioreactors Shortens Timelines & Provides Process Solutions for a Rapid Scale Up (Webinar)

Scale-Out Plus Single-Use Can Multiply Yields (Article)

Capacity Strategies: The Strategies Behind Choosing Between Large-Scale and Single-Use Investments (Article)

Viral Safety in Biomanufacturing (Video)

Ask the Expert Continuous Manufacturing (Article)

Scale-Out vs. Scale-Up GMP Manufacturing (Article)

WuXi Biologics Publications (Archive)

WuXi Biologics Perspectives (Archive)

Awards and Achievements

WuXi Biologics wins 2019 CMO Leadership Awards in all six core categories Read More

WuXi Biologics receives “Asia’s Best CMO of 2018” award from IMAPAC Read More

WuXi Biologics standardizes a remarkable 12 month “DNA to IND” timeline through its streamlined development platform Read More

Notice:

You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?

Yes, continue to proceed

No, stay on this Website